Valneva reports positive three-year antibody persistence data for its single-shot chikungunya vaccine ixchiq®

Saint-herblain (france), december 3, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine ixchiq®. the results are in line with valneva's expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. the three-year persistence data are also in line with positive twelve-month and two-year persistence data the company reported in december 20221 and 20232, respectively.
VALN Ratings Summary
VALN Quant Ranking